US2014234397A1PendingUtilityA1

Treatment of klebsiella pneumoniae with liposomally formulated glutathione

Assignee: BROWN LOU ANNPriority: Feb 15, 2013Filed: Mar 15, 2013Published: Aug 21, 2014

Est. expiryFeb 15, 2033(~6.5 yrs left)· nominal 20-yr term from priority

Inventors:Lou Ann Brown Frederick Timothy Guilford

A61K 9/0014A61K 9/4858A61K 9/006A61K 9/0019A61P 31/04A61K 9/127A61K 38/063A61K 9/0095A61K 9/0053

PatentIndex Score

Cited by

References

Claims

Abstract

The composition of the invention, liposomal glutathione, has been recently shown to have utility for having an antibiotic like effect on Klebsiella pneumonia cultures in vitro, and in vivo as demonstrated by efficacy in reducing by large multiples the presence of cultures of Klebsiella in rats in animal tests. Further, because the liposomal glutathione bolsters body defenses as well as appearing to have direct killing action, the propensity to create more and more resistant strains to antibiotic treatment is downgraded.

Claims

exact text as granted — not AI-modified

1 . The use of a composition of liposomally formulated glutathione for treatment of a mammalian patient having Klebsiella Pneumoniae. 
     
     
         2 . A method of treatment of a mammalian patient having Klebsiella Pneumoniae comprising:
 administering liposomally formulated glutathione

Join the waitlist — get patent alerts

Track US2014234397A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.